Dilemmas in HER2neg EBC

CE / CME

Clinical Dilemmas When Selecting Adjuvant Therapy for HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: July 19, 2024

Expiration: July 18, 2025

Kevin Kalinsky
Kevin Kalinsky, MD, MS

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

According to experts, adjuvant olaparib may be considered for patients with HER2-negative early-stage breast cancer who meet OlympiA criteria for high-risk disease and have which of the following alterations, in addition to germline BRCA1/2 mutations?